Sargramostim (Leukine), a recombinant form of human granulocyte-macrophage colony stimulating factor (GM-CSF) approved for bone marrow stimulation, showed potential as a possible Alzheimer’s disease treatment, a small phase II study suggested.
In a randomized, double‐blind, placebo-controlled trial of 40 people with mild‐to‐moderate Alzheimer’s disease, sargramostim appeared to improve memory, reported Huntington Potter, PhD, of the University of Colorado School of Medicine in Aurora, and colleagues.